Form 4: Castle Biosciences Director Acquires Shares

Castle Biosciences Director Rodney Cotton acquired 13,667 Restricted Stock Units on May 22, 2026, which vest on the earlier of the one-year anniversary of the grant date or the day before the next Annual Meeting.

Summary

• Director Rodney Cotton acquired 13,667 Restricted Stock Units (RSUs) on May 22, 2026.
• These RSUs represent the right to receive one share of Castle Biosciences' Common Stock.
• The RSUs will vest in full on the earlier of May 22, 2027, or the day immediately preceding the next Annual Meeting of Stockholders.
• Following this transaction, Mr. Cotton beneficially owns 32,998 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard equity grant for a director rather than an open market purchase or sale.

Positives

• Director acquisition of stock units can signal confidence in the company's future prospects.
• The acquisition is a direct grant of equity, aligning management's interests with shareholders.

Future Outlook

The RSUs vest on the earlier of May 22, 2027, or the day before the next Annual Meeting of Stockholders, indicating a future potential increase in directly held shares by the director.

Industry Context

StockSavvy.ai notes that insider acquisitions of equity, such as Restricted Stock Units, are common in the biotechnology and life sciences sector as a method of executive compensation and long-term incentive alignment.

Stakeholder Impact

• Shareholders: The acquisition of RSUs by a director aligns their interests with shareholders, potentially signaling confidence in the company's long-term value.

Next Steps

• Vesting of Restricted Stock Units on May 22, 2027, or prior to the next Annual Meeting.
• Potential conversion of RSUs to common stock upon vesting.

Key Dates

Keywords

Castle Biosciences, CSTL, Form 4, SEC Filing, Insider Trading, Restricted Stock Units, Equity Award, Director Compensation